<?xml version="1.0" encoding="utf-8" standalone="yes" ?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>single-cell | OncoRNALab</title>
    <link>https://oncornalab.ugent.be/tags/single-cell/</link>
      <atom:link href="https://oncornalab.ugent.be/tags/single-cell/index.xml" rel="self" type="application/rss+xml" />
    <description>single-cell</description>
    <generator>Source Themes Academic (https://sourcethemes.com/academic/)</generator><language>en-us</language><lastBuildDate>Tue, 31 Mar 2026 09:00:00 +0200</lastBuildDate>
    <image>
      <url>https://oncornalab.ugent.be/images/logo_hu8ef990265eda91976e02b9c834a05170_57383_300x300_fit_lanczos_3.png</url>
      <title>single-cell</title>
      <link>https://oncornalab.ugent.be/tags/single-cell/</link>
    </image>
    
    <item>
      <title>Development of an custom near single-cell spatial transcriptomics platform using photolithography to study cellular heterogeneity induced by targeted therapies in neuroblastoma</title>
      <link>https://oncornalab.ugent.be/poster/bsl_oncopoint_2026/</link>
      <pubDate>Tue, 31 Mar 2026 09:00:00 +0200</pubDate>
      <guid>https://oncornalab.ugent.be/poster/bsl_oncopoint_2026/</guid>
      <description>&lt;p&gt;BACKGROUND: High-risk neuroblastoma accounts for 15% of pediatric cancer mortality, with survival rates stagnating at 50%. While spatial transcriptomics (ST) offers a path to understanding the tumor microenvironment and therapy resistance, current commercial platforms are either cost-prohibitive, low resolutions and/or lack sensitivity required for precious clinical samples.&lt;/p&gt;
&lt;p&gt;AIMS: To develop a high-resolution, cost-effective ST platform (approximately €100/array) tailored for investigating the spatial effects of innovative targeted therapies in neuroblastoma.&lt;/p&gt;
&lt;p&gt;METHODS: Our platform utilizes custom-printed microarrays featuring four subarrays, each containing ± 85,000 spots (13.6 x 13.6 µm) with a 1 µm interspot distance. This architecture provides high spatial resolution across a 10 x 14 mm capture area. To validate the workflow, we performed on-slide fluorescent first and second-strand cDNA synthesis using mouse olfactory bulb as a structural reference tissue. We also assessed the quality of spatial barcodes by cleaving the capture probes and sequencing them.&lt;/p&gt;
&lt;p&gt;RESULTS: Barcode quality was adequate with 70% assignment rate at 99% precision. Proof-of-concept experiments successfully demonstrated transcript capture, with fluorescent footprinting revealing the distinct anatomical layers of the mouse olfactory bulb. This confirms the platform&amp;rsquo;s ability to maintain spatial integrity during enzymatic steps. The platform achieves a &amp;gt;10-fold cost reduction compared to commercial alternatives. Ongoing work focuses on library preparation optimization, integration with arrayed tumor cuboids for high-throughput drug screening, and modifications such as targeted ST for higher sensitivity (at lower cost) and long-read ST.&lt;/p&gt;
&lt;p&gt;CONCLUSIONS: Our platform democratizes spatial profiling for pediatric oncology. By combining affordability with near single-cell resolution, our platform enables deeper investigation into neuroblastoma heterogeneity and supports the development of more effective precision medicine strategies.&lt;/p&gt;
</description>
    </item>
    
  </channel>
</rss>
